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RIPK1 protects from TNF-α-mediated liver damage
during hepatitis
Aveline Filliol1,2,3, Claire Piquet-Pellorce1,2,3, Jacques Le Seyec1,2,3, Muhammad Farooq1,2,3, Valentine Genet1,2,3,
Catherine Lucas-Clerc2,4, John Bertin5, Peter J Gough5, Marie-Thérèse Dimanche-Boitrel1,2,3, Peter Vandenabeele6,7,
Mathieu JM Bertrand6,7,8 and Michel Samson*,1,2,3,8
Cell death of hepatocytes is a prominent characteristic in the pathogenesis of liver disease, while hepatolysis is a starting point of
inflammation in hepatitis and loss of hepatic function. However, the precise molecular mechanisms of hepatocyte cell death, the
role of the cytokines of hepatic microenvironment and the involvement of intracellular kinases, remain unclear. Tumor necrosis
factor alpha (TNF-α) is a key cytokine involved in cell death or survival pathways and the role of RIPK1 has been associated to the
TNF-α-dependent signaling pathway. We took advantage of two different deficient mouse lines, the RIPK1 kinase dead knock-in
mice (Ripk1K45A) and the conditional knockout mice lacking RIPK1 only in liver parenchymal cells (Ripk1LPC-KO), to characterize the
role of RIPK1 and TNF-α in hepatitis induced by concanavalin A (ConA). Our results show that RIPK1 is dispensable for liver
homeostasis under steady-state conditions but in contrast, RIPK1 kinase activity contributes to caspase-independent cell death
induction following ConA injection and RIPK1 also serves as a scaffold, protecting hepatocytes from massive apoptotic cell death
in this model. In the Ripk1LPC-KO mice challenged with ConA, TNF-α triggers apoptosis, responsible for the observed severe
hepatitis. Mechanism potentially involves both TNF-independent canonical NF-κB activation, as well as TNF-dependent, but
canonical NF-κB-independent mechanisms. In conclusion, our results suggest that RIPK1 kinase activity is a pertinent therapeutic
target to protect liver against excessive cell death in liver diseases.
Cell Death and Disease (2016) 7, e2462; doi:10.1038/cddis.2016.362; published online 10 November 2016
Contemporary liver diseases result from chronic conditions,
such as chronic viral hepatitis, nonalcoholic fatty liver hepatitis
(NASH) and alcoholic liver hepatitis.1 The global pandemic of
chronic viral hepatitis (hepatitis B and C virus infections)
affects a significant proportion of the world population,
currently estimated at around 500 million people.2 In parallel,
the prevalence of NASH rises especially in Western countries
because of lifestyle evolution. Untreated, chronic hepatitis
predispose to the development of cirrhosis and hepatocellular
carcinoma (HCC).3 The progression of these diseases is
triggered by hepatocyte death,3,4 and the cell death processes
are starting to emerge. Immune cells, including liver resident
macrophages (Kupffer cells) or infiltrating natural killer (NK)
cells and T cells (natural killer T (NKT) and T lymphocytes),
produce molecules that induce hepatic parenchyma damage.
Immune cells secrete or expressed at their surface tumor
necrosis factor alpha (TNF-α), FAS ligand (FasL) and TNF-
related apoptosis-inducing ligand (TRAIL). These ligands
induce cell death by engaging their respective receptors
(TNFR, Fas and death receptors 4 and 5 (DR4, DR5)) present
at the surface of hepatocytes.5 Receptor interacting protein
kinase 1 (RIPK1) is a key protein regulating signaling
downstream of these DRs, and is best characterized for
its roles downstream of TNFR1.6 Clinical studies have
underlined the crucial role of TNF-α in several liver diseases.
Indeed, serum TNF-α levels increase in patients with
fulminant hepatic failure7 and is correlated with poor
prognostic.8 TNF-α is a master pro-inflammatory cytokine that
binds TNFR1 and TNFR2, but most of its biological activities
have been associated with TNFR1 signaling. Downstream
of TNFR1, RIPK1 functions as a signaling node driving
cell survival as well as caspase-8-dependent apoptosis or
RIPK3/mixed lineage kinase domain-like pseudokinase
(MLKL)-dependent necroptosis.9 These opposed cellular
fates are regulated by two different faces of RIPK1, it functions
as a scaffold to promote cell survival, in part via NF-κB
activation, and as a kinase to induce cell death.6 The
perinatal lethality of RIPK1-deficient mice has long
hampered the in vivo study of the dual faces of RIPK1.10
Recently, the publication of viable and healthy RIPK1
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Figure 1 RIPK1 is dispensable for liver homeostasis under steady-state conditions. (a) Western blot analysis of RIPK1 and β-tubulin in protein extracts issued from
the livers of WTand Ripk1LPC-KO mice. (b) Pictures of liver tissue sections analyzed by IHC for RIPK1 issued from WTand Ripk1LPC-KO mice challenged with PBS. (c) Levels of
serum ALT and AST in unchallenged animals aged 6 and 9 months. (d) Pictures of liver tissue sections, stained by H&E or analyzed by IHC for Ki67, issued from WT
and Ripk1LPC-KO mice aged of 9 months
Figure 2 RIPK1 has pro-necroptotic and anti-apoptotic hepatocyte cell death functions during ConA-mediated hepatitis. (a) Levels of serum ALT 10 h after ConA injection, in
WT mice pretreated or not by Nec-1 S (left panel), or in WTor Ripk1K45A mice (right panel). (b) Survival curve: all WT mice (n= 23) treated with ConA (12 mg/kg) survived and 7
Ripk1LPC-KO mice on 33 died 12 h after ConA injection: kinetics of weight and serum ALT of WTand Ripk1LPC-KO mice after PBS or ConA injection. (c) Pictures of liver tissue
sections, analyzed by IHC for cleaved-caspase-3, issued from mice 7 h after ConA injection (upper panels). Signal quantification of cleaved-caspase-3 (lower panel). (d) Western
blot analysis of cleaved-caspase-3 and β-actin in protein extracts issued from the livers of WTand Ripk1LPC-KO mice, collected 7 h after ConA injection. Positions of molecular
weight markers (kDa) and of studied proteins are respectively indicated on the left and right sides of the gel. (e) Cleaved-caspase-3 staining and (f) amounts of serum ALT in WT
and Ripk1LPC-KO mice, 11 h after ConA challenge with an eventual pre-treatment with a pan-caspase inhibitor (Q-VD-OPh) or only with its vehicle (Cont). For all graphs, each dot
represent an individual and errors bars are expressed as means ±S.E.M. (*, #, $Po0.05; **, ##, $$Po0.01; ***, ###, $$$Po0.001; NS, nonsignificant)
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kinase dead knock-in mice (Ripk1K45A) revealed that only
RIPK1 scaffolding function, and not its kinase activity,
is crucial for homeostasis and viability.11 The generation of
conditional RIPK1-deficient mouse lines also demon-
strated the crucial pro-survival role of RIPK1 in intestinal and
epidermal epithelia and in hematopoietic cells.12–14
RIPK1 functions in the liver, especially under pathological
conditions, have so far remained unclear. The hepatic
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inflammation induced in mice by concanavalin A (ConA)
injection reflects the overall physiopathological conditions
observed in human viral or autoimmune hepatitis.15 In this
model, the combined occurrence of usual cytotoxic effectors
(perforin, granzyme B, TNF-α, FasL and TRAIL) triggers
hepatocyte death and takes part in hepatitis development.16
Indeed, artificial impairment of one effector, or of its cognate
receptor, is sufficient to prevent hepatitis in ConA-challenged
animals.5,17–19 Data suggest implication of RIPK1 kinase
activity in the DR-induced death of hepatocytes in this model.
Indeed, chemical inhibition of RIPK1 seems to protect the
organ from ConA-induced T-cell-mediated injuries.20–22 How-
ever, genetic evidence for the implication of RIPK1 kinase
activity in the death process is still lacking. In addition, whether
RIPK1 also functions as a scaffold maintaining liver home-
ostasis under physiological condition and/or protecting hepa-
tocytes from death under challenged conditions is currently
unknown. Thus, to characterize the role of RIPK1 in hepatitis,
we took advantage of two genetically modified mouse lines,
the RIPK1 kinase dead knock-in mice (Ripk1K45A) and the
conditional knockout mice lacking RIPK1 only in liver
parenchymal cells (Ripk1LPC-KO).
Results
RIPK1 is dispensable for liver homeostasis under steady-
state conditions. In order to evaluate the role of RIPK1 in
liver homeostasis, we generated mice specifically deficient
for RIPK1 in liver parenchymal cell (hepatocytes and
cholangiocytes) (Ripk1LPC-KO) by crossing RIPK1 conditional
mice (Ripk1fl/fl)12 with transgenic mice expressing the Cre
recombinase under the control of the mouse albumin
regulatory elements and α-fetoprotein enhancers (Alfp-
Cre).23,24 Ripk1LPC-KO mice were viable and reached adult-
hood without morphological liver alteration. Western blot and
IHC analyses confirmed RIPK1 expression in the liver
parenchymal cells of the Ripk1fl/fl wild-type (WT) animals
but not of the RipK1LPC-KO littermates (Figures 1a and b).
Monitoring of RipK1LPC-KO mice over a period 9 months did
not revealed occurrence of any obvious abnormality. Even if
liver histology of mature Ripk1LPC-KO mice revealed few
infiltrated immune cells, no inflammation settled. Indeed,
serum transaminase (aspartate amino-transferase (AST) and
alanine amino-transferase (ALT)) levels remained stable and
similar to those of WT littermates (Figure 1c). No changes in
the expression levels of inflammatory cytokines (TNF-α, IFN-γ
and IL-6) were similarly detected (Supplementary Figure 2A).
Finally, Ki67 labeling of liver tissues did not show any
modification in basal cell proliferation rate between the two
genotypes (Figure 1d). Together, these results showed that,
contrary to its role in other tissues,12,13 RIPK1 is dispensable
for proper liver development and homeostasis.
RIPK1 has pro-cell death and anti-apoptotic functions in
hepatocyte during ConA-mediated hepatitis. Next, we
evaluated the role of RIPK1 in liver parenchymal cells under
challenged conditions. We, and others, have previously
reported that ConA injection in mice induces TRAIL-
mediated caspase-independent cell death of hepatocytes,
which can be partially prevented by co-injection of the RIPK1
kinase inhibitor necrostatin-1 (Nec-1), suggestive of necrop-
tosis induction.20 This inhibitor has, however, later been
demonstrated not to be so specific for RIPK1.25,26 We
therefore re-evaluate the implication of RIPK1 enzymatic
activity to ConA-induced hepatocyte death by inhibiting
RIPK1 with Nec-1S, a RIPK1 kinase inhibitor more stable
and specific than Nec-1, and by making use of the RIPK1
kinase dead (Ripk1K45A) mice. Importantly, both approaches
confirmed that RIPK1 kinase activity drives liver injury
induced by ConA, as shown by reduced levels of serum
transaminase in Nec-1S pretreated mice and in Ripk1K45A
mice (Figure 2a).
In order to explore the pro-survival role of RIPK1 in the
ConA-induced acute-hepatitis model, we used the
Ripk1LPC-KO mice that are fully deficient for both RIPK1
scaffold and kinase functions. Although injection of a low dose
(12 mg/kg) of ConA in WT mice provoked a non-lethal
moderate hepatitis, it elicited a fulminant hepatitis in
Ripk1LPC-KO mice leading to 21% lethality (Figure 2b, left). In
both genotypes, the illness induced weight loss because of
poor appetite (Figure 2b, middle) but liver damage were more
pronounced in Ripk1LPC-KO mice, as shown by wider necrotic
areas (Supplementary Figure 1A), higher number of TUNEL-
positive cells (Supplementary Figure 1A) and higher levels of
serum transaminases (Figure 2b,Supplementary Figure 1B).
Cell death in Ripk1LPC-KO mice was apoptosis, as demon-
strated by the important cleaved-caspase-3 staining detected
by histological and western blot analysis (Figures 2c and d).
This active caspase-3 staining was not observed in the WT
littermate. To evaluate the importance of apoptosis in the
fulminant ConA-induced hepatitis observed in Ripk1LPC-KO
mice, we treated mice 1 h before ConA injection with
Q-VD-OPh hydrate (Q-VD-OPh), a pan-caspase inhibitor.
Q-VD-OPh greatly decreased the number of cleaved-
caspase-3-positive cells (Figure 2e) and significantly reduced
hepatolysis, as shown by reduced injured areas in the liver
(Supplementary Figure 1C) and the limited serum levels of
transaminases (Figure 2f,Supplementary Figure 1D). In
conclusion, our results indicated that RIPK1 kinase activity
drives hepatocyte necroptosis following ConA injection but
also serves as a scaffold protecting hepatocytes frommassive
apoptosis in the same model.
RIPK1 limits inflammation in ConA-mediated hepatitis.
The lack of RIPK1 in liver parenchymal cells not only induced
apoptotic cell death but also clearly exacerbated inflamma-
tion in ConA-challenged mice. Indeed, the induced mRNA
levels of the inflammatory cytokines IFN-γ, TNF-α and IL-6
were comparable between the two genotypes 11 h after
ConA injection, but significantly more abundant in the liver of
Ripk1LPC-KO mice 24 h after challenge (Figure 3a). Moreover,
IFN-γ concentrations were significantly higher in the serum of
Ripk1LPC-KO mice at 11 and 24 h post-ConA injection
(Supplementary Figure 2A). Although not statistically sig-
nificant, a similar trend was also observed for TNF-α and IL-6
(Supplementary Figure 2A). In addition, immunolabeling of
liver sections revealed higher hepatic recruitment of
CD45- and CD11b-positive immune cells in Ripk1LPC-KO
individuals (Figure 3b,Supplementary Figure 2B). Sustained
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inflammation in Ripk1LPC-KO mice was also demonstrated by
the fact that hepatic mRNA levels of IL-6, a marker of liver
injury involved in tissue repair, continued to increase at 24 h
post-injection (P.I.) only in these animals (Figure 3a). In line
with this, the number of CD69-positive lymphocytes remained
more elevated in the spleen of Ripk1LPC-KO mice at 24 h,
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Figure 3 RIPK1 limits inflammation in ConA-mediated hepatitis. (a) Levels of hepatic TNF-α, IFN-γ and IL-6 transcripts in WTor Ripk1LPC-KO mice 11 or 24 h after PBS or
ConA injection. (b) CD45 immunofluorescence staining (green) on liver sections collected at the indicated times P.I. and issued from WTor Ripk1LPC-KO mice challenged by PBS
or ConA. Nucleus were stained by Hoechst (blue) and actin by fluorescent phalloidin (red). (c) Levels of hepatic TNF-α, IFN-γ and IL-6 transcripts in WTand Ripk1LPC-KO mice,
11 h after ConA challenge with an eventual pre-treatment with a pan-caspase inhibitor (Q-VD-OPh) or only with its vehicle (Cont). For all graphs, errors bars are expressed as
means ± S.E.M. (*, #Po0.05; **, ##Po0.01; ***, ###Po0.001)
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reflecting prolonged activation of T lymphocytes promoted
by the inflammatory microenvironment (Supplementary
Figure 2C). Importantly, the occurrence of hepatocyte
apoptosis in the liver of Ripk1LPC-KO mice mostly contributed
to the exacerbation of inflammation in these mice, and only to
a limited extent to the establishment of the initial inflammatory
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microenvironment. Indeed, blocking apoptosis by Q-VD-OPh
did not alter the early (11 h) induction of the hepatic TNF-α
and IFN-γ transcripts (Figure 3c), nor the immune cell
recruitment and activity (Supplementary Figures 3A and B).
Nevertheless, Q-VD-OPh still prevented the 11-h induction of
IL-6 mRNA in Ripk1LPC-KO mice (Figure 3c), probably due to
the fact that IL-6 has a key biological function in the liver
regeneration and repair, and therefore lower hepatic damage
induced less of IL-6 transcription. Together, these observa-
tions suggest that the protective effect of Q-VD-OPh on
ConA-treated Ripk1LPC-KO mice was due to the inhibition of
caspase-mediated cell death and not to a major modification
of the inflammatory microenvironment.
The enhanced sensitivity of Ripk1LPC-KO mice to ConA-
induced hepatitis is mediated by TNF-α-promoted apop-
tosis. Our data demonstrated that, contrary to WT litter-
mates, ConA injection resulted in a fulminant hepatitis in
Ripk1LPC-KO mice, in part caused by the sensitization of
RIPK1-deficient liver parenchymal cells to apoptosis. Pre-
vious in vitro and in vivo studies have reported sensitization
of RIPK1-deficient cells to TNF-mediated apoptosis.27,28
Liver expression of TNF-α, and of its receptors TNFR1/2, is
rapidly induced in the ConA-induced hepatitis model
(Figures 3a and c,Supplementary Figures 2A and 4A). To
investigate the role of TNF-α in the apoptosis of Ripk1LPC-KO
during ConA hepatitis, we neutralized TNF-α by injection of
etanercept (ETA), a TNF-α decoy receptor. TNF-α blockade
greatly protected Ripk1LPC-KO mice from the exacerbated
ConA-induced liver damage, as demonstrated by highly
reduced serum levels of transaminases (Figure 4a,
Supplementary Figure 4B), associated with a decrease of
necrotic area and less apoptotic hepatocytes (Figure 4b). Of
note, ETA also reduced the moderate liver damage in the
similarly challenged WT littermates, indicative of a general
role for TNF-α in the establishment of the ConA-induced
hepatitis model (Figure 4a,Supplementary Figure 4B), as
previously reported.17,29,30 To further assess the in vivo role
of RIPK1 in the TNF-α signaling pathway in hepatocytes,
soluble mTNF-α was injected in WT and Ripk1LPC-KO
littermates. Single mTNF-α injection had no effect on the
liver of WT mice, but induced hepatolysis, already detected
6 h after injection, in Ripk1LPC-KO mice. Hepatolysis was
demonstrated by the analyses of serum transaminases
(Figure 4c,Supplementary Figure 4C), liver infiltrate of
immune cells (data not shown) and necrotic areas
(Figure 4d,Supplementary Figure 4D). Hepatocytes died of
apoptosis, as revealed by cleaved-caspase-3 staining
(Figures 4e and f) and absence of phosphorylated MLKL
immunodetection in the liver lysates (Supplementary
Figure 5), a marker of necroptosis. Together, these
experiments demonstrated that TNF-α contributes to ConA-
induced hepatitis, and is responsible for the apoptosis and
hepatitis severity observed in the Ripk1LPC-KO mice.
RIPK1 protects hepatocytes from ConA-mediated apop-
tosis independently of TNF-α-induced canonical NF-κB
activation. In the TNFR1 signaling pathway, RIPK1 func-
tions as a scaffold protein protecting cells from apoptosis by
activating canonical NF-κB-dependent and -independent
responses.10,12,13,27 Canonical NF-κB activation is known to
induce expression of various pro-survival molecules that
prevent caspase activation. As a consequence, NF-κB
inhibition is often used to sensitize cells to TNF-α-induced
apoptosis.31 The canonical NF-κB-independent pro-survival
function of RIPK1 is on the other hand far less understood,
but suggested to rely on TNF receptor-associated factor 2
(TRAF2) stabilization, which prevents non-canonical NF-κB
activation and caspase-8 processing.12,13,27 We observed
that the nuclear translocation of the p65 NF-κB subunit was
significantly reduced in Ripk1LPC-KO hepatocytes 7 h following
ConA injection, indicative of defective canonical NF-κB
activation (Figure 5a). Accordingly, induction of NF-κB-
target gene transcripts (IKK-γ/NEMO, CXCL1, SAA1 and
CCL20) was repressed in the liver of Ripk1LPC-KO mice
(Figure 5b). The role of RIPK1 in ConA-induced canonical
NF-κB activation was independent of its kinase activity, as no
difference was observed in the Nec-1S treated mice or the
Ripk1K45A mice (Supplementary Figure 6). Surprisingly,
although TNF-α greatly contributed to apoptosis in
RIPK1-deficient hepatocytes during ConA hepatitis
(Figures 4a and b), no defect in p65 nuclear translocation or
NF-κB-dependent gene transcription (SAA1, CXCL1 and
CCL20) was observed in the liver of Ripk1LPC-KO mice 30
min after mTNF-α challenge (Figure 5c,Supplementary
Figure 7). By contrast, TNF-α stimulation led to TRAF2
degradation only in Ripk1LPC-KO animals, supporting a defect
in the canonical NF-κB-independent pro-survival pathway
(Figure 5d).
In contrast to primary hepatocytes isolated from WT mice,
RIPK1-deficient hepatocytes died spontaneously after liver
perfusion. Importantly, the death was prevented by seeding
the cells in presence of ETA or with the pan-caspase
inhibitor z-VAD-fmk (data not shown), demonstrating higher
sensitivity of primary RIPK1-deficient hepatocytes to
TNF-α-induced apoptosis. In line with this, TNF-α also only
induced apoptosis in RIPK1-deficient primary hepatocytes
when ETA was used only for seeding but removed before
TNF-α stimulation, as revealed by active caspase-3 staining
(Figure 6a). Consistent with our in vivo results, TRAF2 levels
were also reduced in primary RIPK1-deficient hepatocytes
stimulated with TNF-α (Figures 6a and b). The fact that
Figure 4 Sensitization of Ripk1LPC-KO mice to ConA-induced hepatitis is triggered by TNF-α-mediated apoptosis. (a) Levels of serum ALT and (b) Pictures of liver tissue
sections, stained by H&E (upper panel) or analyzed by IHC for cleaved-caspase-3 (lower panel), issued from mice in WTand Ripk1LPC-KO mice, 11 h after ConA or PBS challenge
with an eventual pre-treatment with ETA. (c) Levels of serum ALT in WTand Ripk1LPC-KO mice, 2 and 6 h after mTNF-α injection. (d) Pictures of liver tissue sections stained by
H&E and (e) analyzed by IHC for cleaved-caspase-3 (left panel) issued from WTand Ripk1LPC-KO mice, 6 h after mTNF-α injection. Signal quantification of cleaved-caspase-3
(right panel). (f) Western blot analysis of cleaved-caspase-3 and β-actin in protein extracts issued from the liver of WTor Ripk1LPC-KO mice, collected 6 h after mTNF-α injection.
For all graphs, each dot represent an individual and errors bars are expressed as means ± S.E.M. (*, #, $Po0.05; **, ##, $$Po0.01; ***, ###, $$$Po0.001; NS, nonsignificant)
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z-VAD-fmk did not block TRAF2 degradation suggests that
TRAF2 acts upstream of caspase activation (Figures 6a and
b). Finally, we observed that RIPK1 deficiency did not
affect canonical NF-κB activation in primary hepatocytes
stimulated with TNF-α in absence or presence of
z-VAD-fmk, as shown by the kinetics of IκBα phosphorylation
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and degradation and by the induction of CCL20, a
NF-κB-responsive gene (Figures 6c and d). Taken together,
our results suggest that the protective role of RIPK1
against ConA-induced hepatocytes apoptosis may involve
both TNF-independent canonical NF-κB activation, as well
as TNF-dependent, but canonical NF-κB-independent
mechanisms.
Discussion
TNF-α has a key role in the initiation of the inflammatory
response during acute or chronic hepatitis caused by viral
infections, steatosis, autoimmunity, alcohol or acetaminophen
consumptions.4,32 The production of TNF-α by liver Kupffer
cells promotes expression of other cytokines and adhesion
molecules that mediates the recruitment and the activation of
Figure 5 RIPK1 protects hepatocytes from ConA-mediated apoptosis independently of TNF-induced canonical NF-κB activation. (a) Pictures of liver tissue sections,
analyzed by IHC for NF-κB-(p65), issued from WTor Ripk1LPC-KO mice 7 h after ConA or PBS injection. Quantifications of hepatocyte nuclear signals are depicted in the bottom
right inset. (b) Levels of hepatic IKK-γ/NEMO, CXCL1, SAA1 and CCL20 transcripts in WTand Ripk1LPC-KO mice 11 h after ConA injection. (c) Pictures of liver tissue sections
analyzed by IHC for NF-κB-(p65) issued from mice 30 min after mTNF-α injection. (d) Western blot analysis of RIPK1, TRAF2 and β-actin in protein extracts issued from the liver
of WTor Ripk1LPC-KO mice, collected 2 h or 6 h after mTNF-α or PBS injection the star shows a nonspecific band. Errors bars are expressed as means ±S.E.M. (*Po0.05;
**Po0.01; ***Po0.001)
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Figure 6 TNF-α induced primary hepatocyte death and TRAF2 destabilization in a NF-κB-independent manner in absence of RIPK1. (a) Western blot analysis of RIPK1,
TRAF2 and cleaved-caspase-3 in protein extracts of primary WTor RIPK1-deficient hepatocytes treated or not with TNF-α with or without z-VAD-fmk, during 1 h or 2 h. (b and c)
Western blot analysis of RIPK1, TRAF2, P-IκBα and β-actin in protein extracts of primary WTor RIPK1-deficient hepatocytes treated or not with TNF-α during 5, 15, 30 min. (d)
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expressed as means ± S.D. (#Po0.05; ##Po0.01; ###Po0.001) and is based on the duplicate of primary hepatocyte cultures and triplicate for qPCR experiment
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immune cells involved in hepatocyte death.33,34 A specific pro-
inflammatory context is needed for the induction of hepatolysis
by TNF-α as injection of TNF-α alone in mice is insufficient to
induce hepatitis. Inhibition of transcription by D-galactosamine
or inactivation of canonical NF-κB signaling is often required to
drive TNF-α-mediated hepatocyte apoptosis.35,36 In the ConA
hepatitis mouse model, which mimics human dysimmune
hepatitis, immune cells activated by the lectin rapidly release
TNF-α that is one of the first cytokines detected in the mouse
serum.29 We found that neutralizing TNF-α with ETA reduced
ConA-induced hepatitis, confirming previous studies indicat-
ing that genetic or chemical inactivation of TNF-α or TNFR1
protects ConA-treated animals from hepatitis.17,29,30 Together,
these results underline the key role played by TNF-α in
hepatitis induction. However, a recent publication reported that
TNF-α does not directly induce hepatocyte death in ConA
hepatitis in contrast to the D-GalN/LPSmodel. Indeed, specific
deficiency for TNFR1 in myeloid derived cells (TNFR1MDC-KO),
but not in liver parenchymal cells (TNFR1LPC-KO), protected
mice from ConA hepatitis.37 These results indicate that TNF-α
promotes inflammatory conditions to provoke liver damage in
the ConA model, but that TNF-α is not a direct inductor of
hepatocyte death. In the TNF-α signaling pathway, RIPK1
governs cell fate.6,38 Our work highlights a dual role of RIPK1
during ConA hepatitis. First, and in accordance with previous
studies,20,39 we found that RIPK1 functions as a kinase
inducing cell death. Indeed, inactivation of RIPK1 activity
either by Nec-1S or genetic modification greatly protected
ConA-challenged mice from hepatitis, demonstrating a key
role of RIPK1 kinase activity in ConA-induced hepatocyte
death. Depending on the cellular conditions, the enzymatic
activity of RIPK1 has been reported capable of mediating
apoptosis or necroptosis, a regulated form of necrosis with
RIPK3 and MLKL as core components.40,41 We found that WT
mice with ConA-induced liver injuries exhibited only few
caspase-3-positive hepatocytes, and that pan-caspase inhibi-
tion by Q-VD-OPh failed to protect these mice from ConA-
induced hepatitis, supportive of necroptosis induction. Never-
theless, because a switch from apoptosis to necroptosis has
been reported in hepatocytes upon caspases inactivation,42,43
future works using hepatocytes-deficient RIPK3 or MLKLmice
will help ruling out the occurrence of RIPK1 kinase-dependent
apoptosis during ConA hepatitis. Next to its pro-death role,
RIPK1 also appeared as a pro-survival scaffold for hepato-
cytes. In accordance with a recently published article, we
found that RIPK1 is nonessential tomaintain liver homeostasis
under physiological condition.44 Nevertheless, mice with liver
parenchymal cells lacking RIPK1 developed fulminant hepa-
titis associated with hepatocyte apoptosis when low doses of
ConA or TNF-α were administrated. This phenotype partly
contrasts with those observed in mice in which RIPK1
deficiency was limited to intestinal epithelial cells or to
keratinocytes.12,13 In these tissues, spontaneous apoptosis
and inflammation arise, likely due to their direct interaction with
commensal bacteria that trigger de novo TNF-α secretion. The
role of TNF-α as a direct mediator of hepatocyte apoptosis in
Ripk1LPC-KO mice is highlighted by the reduction of ConA
hepatitis by ETA or Q-VD-OPh, the induction of liver apoptosis
by a single injection of TNF-α in Ripk1LPC-KO mice, and the
susceptibility of primary RIPK1-deficient hepatocytes to TNF-
α-induced apoptosis. Activation of the canonical NF-κB path-
way may contribute to the protective role of RIPK1 in
hepatocytes but would not be sufficient, and would occur
independently of TNF-α signaling. Indeed, ConA-induced
hepatitis in Ripk1LPC-KO mice was associated with a partial
defect in NF-κB activation, as shown by reduced nuclear p65
labeling and by the lower expression of NF-κB-dependent
genes. However, hepatitis was also detected despite a
widespread activation of the NF-κB signaling pathway in
hepatocytes of TNF-α-treated Ripk1LPC-KO mice. This may be
explained by the quick destabilization of TRAF2, observed
in vivo and in vitro after TNF-α treatment. Accordingly,
published data described different mechanisms by which
RIPK1 may protect cells from TNF-induced death. In mouse
embryonic fibroblasts lacking RIPK1, TNF-α-induced apopto-
sis is correlated to defective canonical NF-κB activation and
consequent c-FLIP dysregulation.12 Besides, RIPK1 would
contribute to cell survival regardless of canonical NF-κB, by its
capacity to stabilize cIAPs and TRAF2 proteins, precluding
non-canonical NF-κB activation, c-FLIP destabilization and
caspase recruitment.12,13,27,45 Of note, the discrepancy
between the defect, or not, in canonical NF-κB activation
following ConA or TNF-α injection could still be explained by
the amount of circulating TNF-α provided in both systems, or
RIPK1-dependent activation of NF-κB by other stimulus than
TNF. Anyway, our results still show TNF-α-induced apoptosis
in RIPK1-deficient hepatocytes despite the ability of NF-κB to
translocate in nucleus, demonstrating a canonical NF-κB-
independent protective role of RIPK1 in these cells, as
previously reported in other cells.12,13,27,45
Figure 7 proposes a schematic model of TNF-α signaling in
hepatocytes of mice challenged with ConA. The lectin
activates T lymphocytes (LT), Kupffer (KC), NK and
NKT cells, which result in the release by these cells of
cytokines, such as TNF-α and IFN-γ. Activation of NKT cells
induces hepatocyte death mediated by TRAIL/DR5 signaling,
and potentially also by TNFR1, which depends on RIPK1
kinase activity. TNF/TNFR1 binding also induces assembly of
complex I by recruitment of TRADD, RIPK1 and TRAF2
preventing caspase activation and limiting cell death. RIPK1
deficiency induces TRAF2 destabilization upon stimulation
and promotes formation of complex II, caspase-8 activation
and apoptosis induction.
This work underlines the interest to focus studies on RIPK1
in other hepatitis models, and especially in acetaminophen
(APAP) liver toxicity, where the role attributed to RIPK1 is not
yet fully understood. Whereas most studies reveal a protective
role of kinase inhibition by Nec-146–48 or RIPK1 knockdown.49
Schneider et al.50 recently suggest that RIPK1 deletion in
hepatocytes has no effect in this hepatitis model. According to
our demonstrated dual role of RIPK1 in hepatocytes, the
kinase pro-death role of RIPK1 should be dissociated from his
scaffolding pro-survival function in these studies by challen-
ging RIPK1 kinase dead (Ripk1K45A) mice with APAP.
Moreover, our data could explain recent results obtained
with of NEMOLPC-KO mice, which presented spontaneous
hepatocyte death.44,51,52 Surprisingly, apoptosis is strongly
prevented by crossing NEMOLPC-KO mice with RIPK1 kinase
dead mice while poorly with Ripk1LPC-KO.44 As NEMOLPC-KO
mice presented elevated TNF-α in the liver compared with WT
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mice,51 additional RIPK1 deficiency could induce hepatocyte
apoptosis in a TNF-α-dependent manner.
In conclusion, our results underline the protective role of
RIPK1 in dysimmune hepatitis and the risks of potential
defects in the RIPK1 scaffolding function that would
sensitize hepatocyte to the death, risking to worsen hepatitis
and even to the increase of HCC onset. Furthermore, our data
pointed out the importance of studying the potential
relationship between the genetic polymorphism of Ripk1 gene
and the predisposition to more severe liver damage in
hepatic infectious or autoimmune diseases. Finally, our results
support also that RIPK1 kinase activity is a pertinent
therapeutic target to protect liver against excessive cell death
in liver diseases.
Materials and Methods
Animals and treatment protocols. Ripk1LPC-KO mice were generated by
crossing Ripk1fl/fl strain11 with Alfp-Cre transgenic mice having a Cre recombinase
driven by the serum albumin gene promoter completed with albumin and
α-fetoprotein enhancers.21 RIPK1 kinase dead knock-in (Ripk1K45A) mice have been
already described.10 In all experiments, genetically modified mice were system-
atically compared with their littermates. Animals were housed in individually
ventilated cages at the VIB Inflammation Research Center in conventional animal
facilities. All experiments on mice were conducted according to Institutional, National
and European animal regulations. In vivo protocols were approved by the ethics
committee of Ghent University. Homogeneous groups of male and female mice at
7–13 weeks of age were used for each experiment. ConA (C2010 Sigma-Aldrich,
St. Louis, MO, USA) diluted at 3 mg/ml in PBS supplemented with MnCl2 0.31 mM
and CaCl2 0.75 mM, was administered by intravenous (i.v.) injection at a dose of
10 or 12 mg/kg body weight. Q-VD-OPh hydrate (Sigma-Aldrich, SML0063) was
injected in mice via the intraperitoneal (i.p.) route (20 mg/kg and 10 μl/g of body
weight) 1 h before ConA injection. Nec-1 s (Biovision Inc., Milpitas, CA, USA,
#2263) was administered by i.v. injection (6.25 mg/kg and 4 μl/g body weight)
15 min before the ConA challenge. An i.p. injection was used to deliver ETA (Enbrel,
Pfizer, New-York, NY, USA) to mice (10 mg/kg and 10 μl/g body weight) 1 h before
ConA injection. Mice were given a single i.v. injection of murine TNF-α (mTNF-α,
Peprotech, Rocky Hill, NJ, USA, 315-01A, 40 μg/ml, at a dose of 10 μg/kg body
weight). The control mice received similar volumes of vehicle in each treatment
group. Times of killing are indicated for each experiment.
RNA analysis. Total RNA was extracted, from mice livers tissues using TRIzol
reagent (Thermo Fisher Scientific, Waltham, MA, USA) and from primary
hepatocytes by using the RNeasy mini kit (Qiagen, #74106). First-strand cDNA
was synthesized using the SuperScriptTM II Reverse Transcriptase (Applied
Biosystems, Foster City, CA, USA). Real-time quantitative PCR was performed
using the fluorescent dye SYBR Green with the double-strand specific SYBR
®
Green system (Applied Biosystems) and the ABI 7000 Prism sequence detector
(Applied Biosystems) or the CFX384 Touch™ Real-Time PCR Detection System
(Bio-Rad). cDNA was used as template for amplification with specific primer pairs
(Table 1). Each measurement was performed in triplicate. The relative gene
expression was normalized against the 18S gene expression. The control mice in
each treatment group served as a reference for messenger RNA (mRNA)
expression (control mRNA level was arbitrarily set at 1).
Histopathological and biochemical studies. Fragments of mouse
livers were fixed in 4% paraformaldehyde and embedded in paraffin for IHC and
hematoxylin and eosin (H&E), or frozen in isopentane cooled with liquid nitrogen for
immunofluorescence studies. For histopathology, H&E staining of liver tissues was
carried out to investigate liver injury. Serum ALT and AST transaminases was
measured according to the IFCC primary reference procedures using Olympus
AU2700 Autoanalyser
®
(Olympus Optical, Tokyo, Japan).
Immunolocalization in liver tissues. For immunolocalization of cleaved-
caspase-3, RIPK1, NF-κB-p65 and Ki67 in liver tissues, paraffin-embedded mouse
liver sections (4–5 μm) were dried 1 h at 58 °C, followed by antigen retrieval and
incubated with primary antibody (Cell Signaling Technology, Danvers, MA, USA,
9661S; 3493; Santa Cruz Biotechnology, Dallas, TX, USA, sc-372, respectively) in a
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Figure 7 Role of RIPK1 in ConA hepatitis model. Schema of cell death pathway
during ConA hepatitis in WT and Ripk1LPC-KO mice. The lectin activates LT, KC, NK
and NKT cells, which result in the release by these cells of cytokines, such as TNF-α
and IFN-γ. Activation of NKT cells induces hepatocyte death mediated by TRAIL/DR5
signaling, and potentially also by TNFR1, which depends on RIPK1 kinase activity.
TNF/TNFR1 binding also induces assembly of complex I by recruitment of TRADD,
RIPK1 and TRAF2 preventing caspase activation and limiting cell death. RIPK1
deficiency induces TRAF2 destabilization upon stimulation and promotes formation of
complex II by caspase-8 and apoptosis induction
Table 1 Sequence of primers used for qPCR
Gene Forward Reverse
Mouse 18S 5′-CGCCGCTAGAGGTGAAATTC-3′ 5′-TTGGCAAATGCTTTCGCTC-3′
Mouse TNF-α 5′-TAGCTCCCAGAAAAGCAAGC-3′ 5′-TTTTCTGGAGGGAGATGTGG-3′
Mouse IL-6 5′-CCGGAGAGGAGACTTCACAG-3′ 5′-CAGAATTGCCATTGCACAAC-3′
Mouse IFN-γ 5′-AGGTCAACAACCCACAGGTC-3′ 5′-ATCAGCAGCGACTCCTTTTC-3′
Mouse-CXCL1 5′-CGCCTATCGCCAATGAGC-3′ 5′-GAACCAAGGGAGCTTCAGG-3′
Mouse TNFR1 5′-CAGAACACCGTGTGTAACTGC-3′ 5′-GCAAGCGGAGGAGGTAGG-3′
Mouse TNFR2 5′-CGCTGGTCTTCGAACTGC-3′ 5′-CAGGAGGACACTTAGCACAGC-3′
SAA1 5′-TGTTCACGAGGCTTTCCAAG-3′ 5′-GTCCTCTGCCGAAGAATTCC-3′
CCL20 5′-TCTGCTCTTCCTTGCTTTGG-3′ 5′-TCACCCAGTTCTGCTTTGG-3′
Mouse-IKK-γ/NEMO 5′-GGTGGAGAGACTGAGCTTGG-3′ 5′-CCTCTAAAGCTTGCCGATCC-3′
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Ventana automated machine (Ventana Medical Systems, USA). Revelation of
primary antibody was carried out using horseradish peroxidase (HRP)-conjugated
secondary antibody (Dako, Glostrup, Denmark) and DAB substrate kit (Ventana
Medical Systems, Tucson, AZ, USA, #760-124). Slides were then counterstained
with hematoxylin. TUNEL analysis was performed on mouse liver sections
incubated after antigen retrieval with a mix composed of terminal transferase
(Roche, Mannheim, Germany, 3333566 011) and digoxigenin-11-UTP (Roche,
#1558706) followed by biotinylated anti-digoxigenin (Sigma, #B7405) and counter-
stained with hematoxylin.
For immunolocalization of CD11b and CD45 in liver tissues, cryosections of mouse
liver tissues (8 μm) were successively fixed with paraformaldehyde 4%, treated
with NH4Cl 0.1 M, blocked with 2–4% BSA and incubated with primary antibody
(BD Pharmingen, San Jose, CA, USA, #552850 and #553079; respectively) at
4 °C overnight. Revelation of primary antibody was carried out using DyLight 649-
conjugated donkey anti-rat IgG secondary antibody (Jackson ImmunoResearch
Laboratories, Baltimore, PA, USA). Nuclei were stained with Hoechst (Invitrogen,
H3570) and F-actin with Phalloïdine FluoProbes-547H (Interchim, Montluçon, France,
BZ9620). Image analysis and merged were performed with SpotAdvanced software
(Diagnostic Instruments, Sterling Heights, MI, USA). Quantification of cleaved-
caspase-3 positive-signal was performed with image analysis software (NIS-Element
AR analysis software, Nikon, Tokyo, Japan) and measured to cover an area of
4.3–6 mm2. The quantification hepatocytes with nuclear NF-κB, labeled nuclei were
counted on 3–4 independent fields to cover an area of 3.54–4.72 mm2.Pictures
presented in the figures are issued from animals with ALTor quantified staining values
close to the average obtained for the membership group.
Protein extraction and western blotting. Primary hepatocytes and
mouse liver specimens were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4; 1% Triton
X-100; 25 mM HEPES; 150 mM NaCl; 0,2% SDS; 5 mM MgCl2; 1 mM Na3VO4;
1 mM NaF and proteases inhibitors (Roche, #04 693 132 001)), and liver were
crushed with UltraTurax. After 40 min in ice, samples were centrifuged at 13 000 g.
Proteins from supernatant were assayed with the Bradford method (Bio-Rad).
Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membrane.
Membranes were blocked with non-fat milk or BSA 3–5% in TBS (20 mM Tris,
137 mM NaCl) during 1–2 h and incubated overnight with primary antibody anti-
cleaved-caspase-3, anti-RIPK1 (Cell Signaling) anti-actin (Sigma A3854), anti-TRAF2
(Santa Cruz Biotechnology, sc-876), anti-phospho-IκBα (Cell Signaling, #2859) or
anti-IκBα (Santa Cruz Biotechnology, sc-371) at 4 °C, and then with secondary goat
anti-rabbit immunoglobulins/HRP (Dako, P0448). Protein–antibody complexes were
revealed by enhanced chemiluminescence (Millipore, Billerica, MA, USA) and
ImageQuant LAS-4000 mini imager analysis (GE Healthcare, Chicago, IL, USA).
Primary hepatocyte isolation and culture. Hepatocytes were isolated
from adult C57BL/6 WTand Ripk1LPC-KO mice by the retrograde perfusion approach.23
Mice were previously anesthetized by i.p injection of a ketamine (ImalgeneTM, Merial
Lyon, France, supplier) and xylazine (RompunTM, Bayer, Leverkusan, Germany,
supplier) cocktail (60 and 10 mg/kg of live body weight, respectively) diluted in PBS.
After laparotomy, the liver, perfused through inferior vena cava, was first washed
with solution I (8 g/l NaCl, 0.2 g/l KCl, 0.1 g/l Na2HPO4. 12 H2O and 2.38 g/l Hepes,
pH 7.6) at a 5.5 ml/min flow rate for 8–10 min. Then, the perfusion solution I was
supplemented with 5 mM CaCl2.2H2O and 0.01% collagenases (Liberase
TM TM
Research Grade, Roche) for 5–7 min. Hepatocytes were harvested after three
centrifugations at 90 g for 1 min and an additional purification of viable cells on a
percoll cushion. Cell suspensions, with over 90% viability, were seeded at a density
of 0.1 × 106 cells/cm2 in 24-well plates, previously coated with collagen type I
(BD Biosciences, Le Pont de Claix, France), in Williams’ E medium supplemented
with 10% (vol/vol) fetal calf serum, 2 mM glutamine, 10 IU/ml penicillin, 10 μg/ml
streptomycin and 5 μg/ml insulin. Seeding medium was removed after a 4-h period
and replaced by a similar supplemented Williams’ E medium, without fetal calf serum
but with 1 mg/ml bovine serum albumin, but with 1 μg/ml of ETA and optionally with
10 μM of z-VAD-fmk. After two or three washes, cells were stimulated with 10 ng/ml of
mTNF-α (Peprotech, 315-01A), and used for RNA or protein extraction. Experimental
protocol was conducted in compliance with French laws and the institution’s guidelines
for animal welfare (agreement of M Samson # A3523840).
Serum cytokine immunoassays by flow cytometry. Murine TNF-α,
IFN-γ and IL-6 cytokines were quantified by bead-based immunoassays according
to the manufacturer protocol, using a filter plate and a vacuum filtration system for
washing steps (BioLegend’s LEGENDPLEX, multi-analyte flow assay kit, San Diego,
CA, USA). Samples were analyzed on FC500 cytometer (Beckman Coulter, Brea,
CA, USA).
Immune cells analysis by flow cytometry. Immune cells were prepared
from spleen or liver crushed on a 70 μm filter. Liver immune cells were isolated after
sedimentation and cell fractionation on a 35% Percoll layer. For each organ, red
blood cells were lysed with the ammonium-chloride-potassium (ACK) buffer. To
exclude dead cells from analysis, cell suspensions were labeled for 30 min with
LIVE/DEAD fixable yellow stain (Life Technologies, Carlsbad, CA, USA, L34959).
Cells were also pre-incubated with an anti-CD16/32 antibody (BD Pharmingen) to
block nonspecific binding, before the incubation with the appropriate fluorochrome-
conjugated antibodies (BD Pharmingen, eBioscience, San Diego, CA, USA): anti-
CD3-FITC (clone 17A2), anti-TCRβ-V450 (clone H57-597), anti-CD69-PE (clone
H1.2F3), anti-CD19-APC (clone 1D3), anti-NK1.1-PerCP-Cy-5.5 (clone PK136),
anti-CD4-PE-Cy7 (clone RM4-5), anti-CD8-APC-Cy7 (clone 53-6.7), anti-GR1-
eFluor450 (clone FB6-8C5) or anti-CD11b-PE-Cy7 (clone M1/70). The stained cells
were analyzed on FACSAria™ II flow cytometer using BD FACSDiva software
(BD Bioscience), and data were analyzed with the CXP software (Beckman
Coulter). Doublet and dead cells were excluded, respectively, on the basis of forward/
side scatter and with the LIVE/DEAD labeling. The used immuno-phenotyping was
as followed: Lymphocyte B (LyB): CD19+/CD3- cells; Lymphocyte T (LyT): CD3
+/TCRVβ+/NK1.1-; NKT cells: CD3+/ TCRVβ+/NK1.1+; NK cells: CD3-/NK1.1+;
granulocytes: GR1+CD11b+. Lymphoid activation was studied by analyzing the
expression of CD69. To calculate percentage of each immune cell population, we
considered as 100% of immune cells the sum of events of each immune cell
population analyzed (sum of LyT, LyB, NK cells, NKT cells and granulocytes).
Statistical analysis. Data were expressed as means ±S.E.M. for all mice
treated similarly. Kruskal–Wallis one-way analysis of variance (ANOVA) was
performed, and mean differences between experimental groups were assessed
using the non-parametric Mann–Whitney U-test with the GraphPad Prism5 software
(GraphPad, La Jolla, CA, USA). The significance is shown as follows: *Po0.05,
**Po0.01, ***Po0.001, WT versus RIPK1 mice. #Po0.05, ##Po0.01, ###Po0.001,
mice treated with ConA, or TNF-α versus mice treated with PBS. $Po0.05, $
$Po0.01, $$$Po0.001 mice treated with ConA, or TNF-α at an indicated time versus
mice treated with ConA, or TNF-α at another time in same genotype.
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